Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07237269 · ClinicalTrials.gov registry record · Phase 2
Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer
A Phase 2 study, sponsored by University of Nebraska.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
NCT07237269 is a Phase 2 study that is actively recruiting participants, run by University of Nebraska. The registered enrollment target is 140 participants.
The verdict
NCT07237269, a Phase 2 study, is actively recruiting participants, sponsored by University of Nebraska.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
Study Summary
The advent of PSMA-PET has improved sensitivity and specificity in staging prostate cancer, particularly in intermediate- and high-risk disease. This has created uncertainty in the management of patients with PSMA-positive but conventionally negative pelvic lymphadenopathy (i.e., \<1 cm in smallest diameter). This study evaluates outcomes of enhanced androgen deprivation therapy (ADT) with abiraterone and prednisone compared to standard ADT, both in combination with radiation therapy, in patients with prostate cancer and PSMA-positive but conventionally negative pelvic lymphadenopathy. A total of 140 eligible participants will be randomized to receive either enhanced ADT with abiraterone and prednisone or standard ADT, both with concurrent radiation therapy. Participants will be followed for 5 years after completion of ADT to assess outcomes. The primary objective is to determine whether enhanced ADT improves 5-year failure-free survival compared to standard ADT. Secondary objectives include evaluation of toxicity, quality of life, biochemical progression-free survival, cancer-specific survival, overall survival, and metastasis-free survival. Exploratory objectives include evaluation of tumor growth and regression rates using PSA values and assessment of the relationship between treatment outcomes and blood-based heme oxygenase-1 (HO-1) levels.
Interventions
- RADIATION Radiation Therapy
- DRUG Prednisone
- DRUG Abiraterone
- DRUG Androgen Deprivation Therapy (ADT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2026-04-03 |
| Est. Completion | 2033-04-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07237269
The ClinicalTrials.gov registry entry for NCT07237269 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Radiation Therapy is the first listed.
NCT07237269 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07237269 about?
NCT07237269 is a clinical study titled "Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer". The advent of PSMA-PET has improved sensitivity and specificity in staging prostate cancer, particularly in intermediate- and high-risk disease. This has created uncertainty in the management of patients with PSMA-positive but conventionally negative pelvic lymphadenopathy (i.e., \<1 cm in smallest ...
What is the current status of trial NCT07237269?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2026-04-03. Estimated completion is 2033-04-03.
What interventions are being tested in trial NCT07237269?
The interventions under investigation include: Radiation Therapy (RADIATION), Prednisone (DRUG), Abiraterone (DRUG), Androgen Deprivation Therapy (ADT) (DRUG).
Who is sponsoring clinical trial NCT07237269?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.